AUDIO-Glaxo sees 50/50 split with Merck in cancer vaccine market

November 13, 2007

garnier.jpgGlaxoSmithKline may trail Merck & Co in bringing to market a vaccine for cervical cancer, but Glaxo CEO JP Garnier says its Cervarix will eventually split the market with Merck’s Gardasil. 

Cervarix is already available in Europe, but is still pending approval in the United States, where Gardasil is well established. It may take a few years, but Garnier tells the Reuters Health Summit in a phone interview this week that Glaxo will build the brand and catch-up.

No comments so far

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/